

10/02/00

Jc715 U.S. PTO

10-03-00

A

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional  
applications under 37 CFR 1.53(b))

Title of Invention

METHOD OF ALTERING SHINGOLIPID  
METABOLISM AND DETECTING FUMONISIN  
INGESTION AND CONTAMINATION

Named Inventor(s)

Alfred H. Merrill, Jr.  
Elaine W. Wang  
Dennis C. Liotta  
Ronald R. Riley

Attorney Docket

18085.105133Div3

Express Mail Label No.

EF045414427US

Jc922 U.S. PTO

09/676835

10/02/00

## APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner of Patents  
Box Patent Application  
Washington, D.C. 20231

## ACCOMPANYING APPLICATION PARTS

1. ☒ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification, Claims,  
and Abstract Total Pages 50-49
3. ☒ Drawings Total Sheets 11
4. Oath or Declaration Total Pages 3
  - a. ☐ Newly executed (original or copy)
  - b. ☒ Copy from prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17  
completed)  
[Note Box 5 Below]  
(i) ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting  
inventor(s) named in the prior  
application, see 37 CFR 1.63(d)(2)  
and 1.33(b).
5. ☒ Incorporation by Reference  
(usable if Box 4b is checked)  
The entire disclosure of the prior application, from  
which a copy of the oath or declaration is supplied  
under Box 4b, is considered as being part of the  
disclosure of the accompanying application and is  
hereby incorporated by reference therein.
6. ☐ Microfiche Computer Program (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence  
Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above  
copies

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☒ 37 CFR 3.73(b) Statement  
(when there is an assignee)  
☒ Power of Attorney by assignee
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)  
PTO-1449  
☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☐ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ Small Entity Statement(s)  
☐ Statement filed in prior application  
Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
16. ☐ Other: \_\_\_\_\_

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:  
☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08/627,499

18. CORRESPONDENCE ADDRESS:

Sherry M. Knowles, Esq.  
KING & SPALDING  
45<sup>th</sup> Floor  
191 Peachtree Street, N.E.  
Atlanta, Georgia 30303

By: Sherry Knowles

Sherry M. Knowles, Reg. No. 33,052  
Date: October 2, 2000  
Telephone: 404.572.4600  
Facsimile: 404.572.5145

CERTIFICATE OF EXPRESS MAILING


I hereby certify that the this Divisional Application along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Express Mail on the date shown below with sufficient postage in an envelope with label EF045414427US addressed to, Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



Charles Vorndran  
U.S. Reg. No. 45,315

Date: October 2, 2000

JC922 U.S. PTO  
09/676835  
10/02/00




U.S.S.N.: 08/627,499  
Filed: April 4, 1996  
Transmittal of Issue Fee

JCS22 U.S. PRO  
09/676835  
10/02/00

The Commissioner is authorized to charge any deficiencies or credit any overpayments associated with this paper to Deposit Account No. 11-0980.


Respectfully submitted,

  
Sherry M. Knowles  
Reg. No. 33,052

KING & SPALDING  
191 Peachtree Street  
Atlanta, GA 30303-1763  
Telephone: (404) 572-3541  
Facsimile: (404) 572-5145

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the this Preliminary Amendment along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Express Mail on the date shown below with sufficient postage in an envelope with label EF045414427US addressed to, Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

  
Charles Vorndran  
U.S. Reg. No. 45,315

Date: October 2, 2000

**FEE TRANSMITTAL**Attorney Docket No. **18085.105133Div**

This sheet accompanies a patent application transmittal for the following application:

Inventor(s): **Merrill et al.**Filing Date: **herewith**Title: **METHOD OF ALTERING SHINGOLIPID METABOLISM AND DETECTING FUMONISIN INGESTION AND CONTAMINATION**

The filing fee is calculated as shown below:

**1. FILING FEE:**

		SMALL ENTITY		LARGE ENTITY	
FOR:		FEE	FEE PAID	FEE	FEE PAID
<input checked="" type="checkbox"/> UTILITY FILING FEE		\$355		\$710	710
<input type="checkbox"/> DESIGN FILING FEE		\$160		\$320	
<input type="checkbox"/> PLANT FILING FEE		\$245		\$490	
<input type="checkbox"/> REISSUE FILING FEE		\$355		\$710	
<input type="checkbox"/> PROVISIONAL FILING FEE		\$75		\$150	
SUBTOTAL (1)			\$xxx		\$710

**2. CLAIMS:**

				SMALL ENTITY		LARGE ENTITY	
FOR:	NO. FILED	NO. EXTRA	RATE	FEE		RATE	FEE
TOTAL CLAIMS	24 - 20 =	4	x 9 =			x 18 =	72
INDEP. CLAIMS	5 - 3 =	2	x 40 =			x 80 =	80
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED			+135 =			+270 =	
SUBTOTAL (2)					\$xxx		\$152

**ADDITIONAL FEES:**

		SMALL ENTITY		LARGE ENTITY	
FOR:		FEE	FEE PAID	FEE	FEE PAID
<input type="checkbox"/> LATE FILING, FEE OR OATH		\$65		\$130	
<input type="checkbox"/> NON-ENGLISH SPECIFICATION		\$130		\$130	
<input type="checkbox"/> OTHER					
SUBTOTAL (3)			\$xxx		\$xxx

**TOTAL FILING FEES: \$ 862**

A check is enclosed for the total amount: \$ 710

☒ Charge the deficiency and any additional fees required under 37 C.F.R. 1.16 or 1.17 to Deposit Account 11-0980.

KING & SPALDING  
45<sup>th</sup> Floor, 191 Peachtree Street, N.E.  
Atlanta, Georgia 30303  
Telephone: 404.572.4600

By: Sherry M. Knowles  
Sherry M. Knowles, Attorney for Applicant  
Reg. No. 33,052

Date: October 2, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alfred H. Merrill, Jr. et al.

Serial No.:

Filed: herewith

For: METHOD OF ALTERING SHINGOLIPID METABOLISM AND DETECTING  
FUMONISIN INGESTION AND CONTAMINATION

Assistant Commissioner for Patents  
Box Patent Appliation  
Washington, DC 20231

**Preliminary Amendment**

Sir:

Please amend the above-identified application as follows.

In the Specification

On page one, line 3, please insert the following.

-- This application is a divisional of U.S.S.N. 08/627,499 filed on April 4, 1996,  
now allowed, which was a divisional of U.S.S.N. 08/042,147, filed on April 2, 1993, now U.S.  
Pat. No. 5,518,879 which is a divisional of U.S.S.N. 07/740,426, filed on August 5, 1991, now  
U.S. Pat. No. 5,232,837.

--

In the Claims

Please cancel claims 19-26, 31-36, and 39-46.

METHOD OF ALTERING SPHINGOLIPID METABOLISM  
AND DETECTING FUMONISIN INGESTION AND CONTAMINATION

Throughout this application, various  
5 publications are referenced. The full citation of these  
publications is provided in a bibliography immediately  
before the claims. The disclosures of these publications  
are hereby incorporated by reference to more fully  
describe the state of the art at the time the invention  
10 was made.

The following invention was made through support  
from grant number GM 33369 from the National Institutes of  
Health, grant number DCB 8710283 from the National Science  
15 Foundation and grant number CRIS 6612-42000-004 to the  
United States Department of Agriculture. The United  
States government has rights in the invention.

BACKGROUND OF THE INVENTION

20 Fusarium moniliforme (Sheldon) is one of the  
most prevalent fungi on maize, other grains, and  
agricultural commodities in the United States and  
throughout the world (1). Culture materials from certain  
25 isolates of (and grains naturally contaminated with) F.  
moniliforme have been shown to be toxic and carcinogenic  
for animals (2-5); furthermore, consumption of  
contaminated maize has been correlated with esophageal  
cancer in areas of southern Africa, China, and other  
30 countries (6-8). Several mycotoxins, termed fumonisins,  
have been isolated from extracts of F. moniliforme (9) and  
naturally contaminated corn (10,11). Fumonisin B<sub>1</sub> has been  
shown to cause equine leucoencephalomalacia (12), porcine  
pulmonary edema (13), and promotion of liver tumors in  
35 rats (14). Recent surveys indicate that high levels of  
fumonisin B<sub>1</sub> are present on United States feeds associated  
with field cases of these animal diseases (15).

The molecular mechanism of action of the fumonisins is not known. However, this invention provides the discovery that these compounds bear a remarkable structural similarity to sphingosine, the long-chain (sphingoid) base backbone of sphingomyelin, cerebroside, sulfatides, gangliosides and other sphingolipids. Sphingolipids are thought to be involved with the regulation of cell growth, differentiation, and neoplastic transformation through participation in cell-cell communication and cell-substratum interactions; and possible interactions with cell receptors and signalling systems (16-20). This invention provides that fumonisins and fumonisin analogs target the disruption of sphingosine metabolism and that fumonisins and fumonisin analogs inhibit de novo sphingolipid biosynthesis in animals. This invention further identifies the reactions catalyzed by ceramide synthase as important sites for altering sphingolipid metabolism. This core discovery of the biochemical action of fumonisins provides a means to treat the many diseases associated with sphingolipid metabolism as well as a means for early detection of fumonisin contamination or ingestion.

SUMMARY OF THE INVENTION

This invention provides a method of altering the metabolism of sphingolipids in a cell, comprising  
5 contacting the cell with a fumonisin or an analog thereof. Also provided is a method of treating an abnormal condition in a subject associated with an alteration in sphingolipid metabolism comprising administering a fumonisin, or an analog thereof, to the subject in a  
10 metabolism altering amount. In addition, a composition comprising a fumonisin, or an analog thereof, in a pharmaceutically acceptable carrier is provided. As used herein "a fumonisin" only includes those fumonisins with the metabolism altering activity.

15

Also provided is a method of treating an abnormal condition in a subject associated with the ingestion of a fumonisin, or an analog thereof, which results in the depletion of a sphingolipid in the subject,  
20 comprising adding an amount of the sphingolipid to the subject sufficient to treat the condition. Further provided is a method of treating an abnormal condition in a subject associated with the ingestion of a fumonisin, or an analog thereof, which results in the accumulation of a  
25 sphingolipid, comprising adding an amount of an inhibitor of the sphingolipid to the subject sufficient to treat the condition.

The invention also provides a method of  
30 detecting the consumption of a fumonisin, or an analog, thereof, in a subject comprising (A) detecting, in a sample from the subject, the state of the metabolic pathway of sphingolipids and (B) comparing the state of the metabolic pathway to that of a normal subject, the  
35 presence of a change in the state of the metabolic pathway indicating the consumption of a fumonisin or a fumonisin analog. Also provided is a method of detecting the

presence of a fumonisin or fumonisin analog contamination in a sample from a food or feed comprising detecting a reaction in the metabolic pathway of sphingolipids, the presence of the reaction indicating the presence of a  
5 fumonisin or fumonisin analog contamination.

Furthermore, the invention provides a method of diagnosing an abnormal condition in a subject associated with an alteration in sphingolipid metabolism comprising  
10 detecting the state of the metabolic pathway of sphingolipids in a subject and comparing the state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the presence of an abnormal condition.

15

Finally, this invention provides for novel fumonisin analogs and compositions comprising fumonisins and fumonisin analogs.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. shows structures of sphingosine, Alternaria toxins, fumonisin analogs and fumonisins B<sub>1</sub> and B<sub>2</sub>.

Fig. 2 shows sphingosine biosynthesis and inhibition by fumonisin B<sub>1</sub>. Free long-chain bases (3-ketosphinganine, sphinganine, and sphingosine) have not been found to accumulate as detectable intermediates of this pathway under normal conditions; therefore, sphingosine formation is assessed by hydrolyzing the N-acyl products and analyzing the labelled long-chain bases as depicted in this figure. The chromatograms illustrate the labelling of sphinganine and sphingosine obtained by acid hydrolysis of the lipid extracts from hepatocytes incubated for 2 h with [<sup>14</sup>C]serine with and without 1 μM fumonisin B<sub>1</sub>. The large amount of radiolabel that migrates with the solvent front is primarily fatty acids.

Fig. 3 shows time and concentration dependence of the inhibition of [<sup>14</sup>C]serine incorporation into [<sup>14</sup>C]sphingosine by fumonisins B<sub>1</sub> and B<sub>2</sub>. Panel A: relative amounts of [<sup>14</sup>C]sphingosine formed from [<sup>14</sup>C]serine by hepatocytes exposed to no fumonisin B<sub>1</sub> (none), to 1 μM fumonisin B<sub>1</sub> and [<sup>14</sup>C]serine for 2 h (2 h), upon pretreatment with 1 μM fumonisin B<sub>1</sub> for 16 h followed by incubation with [<sup>14</sup>C]serine for 2 h, and to 1 μM fumonisin B<sub>1</sub> or B<sub>2</sub> and [<sup>14</sup>C]serine for 16 h. Panel B: concentration dependence of fumonisin B<sub>1</sub> inhibition of [<sup>14</sup>C]serine incorporation into [<sup>14</sup>C]sphingosine by rat liver hepatocytes. The assay conditions for this experiment were the same as for the 2 h incubations described in Fig. 2, and each data point represents the mean ± SD for triplicate dishes of hepatocytes. All of the groups were significantly different from the untreated control (P < 0.05).

Fig. 4 shows increases in sphinganine upon incubating hepatocytes with fumonisin B<sub>1</sub>. A: Amounts of label detected in [<sup>14</sup>C]sphinganine; the conditions for these analyses were the same as in Figs. 2 and 3; B: Mass amounts of sphingosine and sphinganine after incubation of hepatocytes with fumonisin B<sub>1</sub> for 2 h, with analysis of the free long-chain bases by HPLC (28); C: HPLC profile of the free long-chain bases of rat liver hepatocytes after incubation with 1 μM fumonisin B<sub>1</sub> for 2 h (for comparison with the usual HPLC profile of untreated liver see reference 28); D: Inhibition of [<sup>3</sup>H]sphingosine conversion to ceramides by fumonisin B<sub>1</sub>. Hepatocytes were incubated with 1 μM fumonisin B<sub>1</sub> for 1 h, then approximately 1 μCi of [<sup>3</sup>H]sphingosine was added and the cells were incubated for the times shown. The lipids were extracted and analyzed by TLC as described in the text. Asterisks designate the groups that are different from control (no fumonisin treatment) with P < 0.05.

Fig. 5 shows inhibition of ceramide synthase by fumonisin B<sub>1</sub> in vitro.

Fig. 6 shows inhibition of de novo sphingosine production upon incubation of rat hepatocytes with Alternaria toxins (AAL toxins).

Fig. 7 shows the concentration of sphingosine, sphinganine and their ratio over time in the plasma of a pony fed fumonisin-contaminated food.

Fig. 8 shows the plots of AST/SGOT and sphinganine to sphingosine ratio over time in the plasma of a pony fed fumonisin-contaminated feed at 15 and 22 ppm fumonisin B<sub>1</sub>.

Fig. 9 shows the synthesis of a fumonisin analog.

Fig. 10 shows reaction schemes which can be employed to control the stereochemistry of the 2-aminopenta-3,5-diol head group during the synthesis of a fumonisin analog.

5

Fig. 11 shows various reaction schemes that can be employed to control the stereochemistry of the aminotriol head groups present in Alternaria toxins or fumonisin analogs similar to Alternaria toxins.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides the core discovery that fumonisins, and their analogs, affect the biosynthetic  
5 pathway of sphingolipids. Fumonisins and their analogs  
are generally referred to collectively as "fumonisin" or  
"fumonisins" herein. However, analogs may also be  
specifically addressed at various times in the  
specification. "Purified fumonisin" means a fumonisin  
10 separated from at least some contaminants associated with  
fumonisins occurring in nature.

Thus, the present invention provides a method of  
altering the metabolism of sphingolipids in a cell  
15 comprising contacting the cell with a metabolism altering  
amount of a fumonisin, or an analog thereof. In  
determining the precise mechanism through which fumonisins  
act, it has been discovered that the alteration in  
metabolism is effected by the fumonisin, or an analog  
20 thereof, binding to ceramide synthase in the conversion of  
sphinganine to dihydroceramide. Additionally, the  
invention provides that the alteration in metabolism can  
be effected by fumonisin, or an analog thereof, binding to  
ceramide synthase in the conversion of sphingosine back to  
25 ceramide. However, the fumonisins could act on various  
other aspects of the sphingolipid biosynthetic pathway and  
thus are not limited by the particular pathway so long as  
sphingolipid metabolism is altered.

30 As used herein, "ceramide synthase" means an  
enzyme or enzymes which add in N-acyl linkage to  
sphingosine, sphinganine and other long-chain bases.  
Thus, both sphinganine N-acyltransferase, which catalyzes  
the conversion of sphinganine to dihydroceramide, and  
35 sphingosine N-acyltransferase, which catalyzes the  
conversion of sphingosine to ceramide, are referred to as  
ceramide synthase herein. As also used herein, "analog of

dihydroceramide or ceramide" means a compound which can be catalyzed by a fumonisin or an analog.

This invention demonstrates that fumonisins can  
5 alter the metabolism of sphingolipids. The invention  
provides the discovery that fumonisins have a structure  
similar to sphingosine. Thus, the activity of the  
fumonisins likely relates to this structural similarity.  
In this regard, the fumonisins and sphingosine share a 2-  
10 amino-3-ol head group and possess backbone carbon chains  
of approximately equal size. However, sphingosine is  
hydroxyl-substituted at carbon 1 while fumonisin B<sub>1</sub> and B<sub>2</sub>  
are hydroxyl-substituted at carbon 5. In addition, the  
fumonisins possess polycarboxylate moieties attached to  
15 the tail of the backbone carbon chain. Thus, these  
similarities and differences between sphingosine in their  
head groups and tails are responsible for the activity of  
the fumonisins. Moreover, one merely needs to make  
various analogs based on these principles and test the  
20 analogs to determine if they have sphingolipid metabolism  
affecting activity. Such making can be done using  
techniques set forth herein. Modifications on these  
techniques to obtain additional analogs would be standard.  
Likewise, these compounds, once synthesized, could be  
25 tested for activity using the methods set forth below.

Thus, "fumonisin analog" as used herein is given  
a function as well as structural definition. "Fumonisin  
analog" means any compound which has structural similarity  
30 to fumonisin B<sub>1</sub>, B<sub>2</sub>, B<sub>3</sub> or B<sub>4</sub> and can alter the metabolism  
of sphingolipids. By structural similarity to a  
fumonisin, we mean analogs comprised of three basic units  
as given in Fig. 1: (a) a 1-aminobutan-2-ol head group  
which may be further substituted by substituents X, Y and  
35 IV; (b) a Spacer Group consisting of an alkyl,  
hydroxyalkyl or dihydroxyalkyl chain (straight or  
branched); (c) a hydrophilic tail (Z-W) in which Z

contains an oxygen or nitrogen atom which can be further functionalized to attach mono- or polycarboxylate moieties (W). In this structure, the Spacer Group = alkyl, hydroxyalkyl or dihydroxyalkyl (straight chain or

5 branched,  $C_1 - C_{20}$ ); Z = H, O, NH, NQ, NQC(O), NHC(O),  $CO_2$ , C(O)NH, C(O)NQ, wherein Q is an alkyl (straight chain or branched,  $C_1 - C_6$ ); W = no substituent, H, alkyl (straight chain or branched,  $C_1 - C_6$ ), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or

10 branched,  $C_1 - C_6$ ) or halo),  $C(O)(CH_2)_nCO_2H$  (where  $n = 1 - 6$ ),  $C(O)(CH_2)_nCW'CO_2H$ , where W' is selected independently from H, alkyl (straight chain or branched,  $C_1 - C_6$ ), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched,  $C_1 - C_6$ ) or halo),

15  $(CH_2)_nCO_2H$  and  $n = 1 - 6$ ; X = H, methyl,  $CH_2OH$  (and esters thereof),  $CH_2NQ'_2$  (where Q' is selected independently from H, alkyl (straight chain or branched,  $C_1 - C_{20}$ ), acyl (C(O)Q" where Q" is an alkyl, straight chain or branched,  $C_1 - C_{20}$ )); and V and Y = H or OH (and esters thereof).

20 Also, explicitly included in the term "fumonisin analog" are the Alternaria toxins (AAL toxins) as given in Fig. 1 and discussed in reference 33 and, by inference, similar compounds produced by other plants and fungi. Specific structures of various analogs and general synthesis

25 methods are set forth below and in Figs. 1, 9 and 10.

"Altering the metabolism" as used herein means either an increase or a decrease in the concentration of compounds formed in the sphingolipid biosynthetic pathway

30 depending on what point in the pathway is affected. Typically, since ceramide synthase (sphinganine-N-acyltransferase) is generally bound by the fumonisin or fumonisin analog, and ceramide synthase (sphinganine-N-acyltransferase), which can also be bound by fumonisins,

35 catalyzes the conversion of sphinganine to dihydroceramide in the pathway, the concentration of any compound above the site of action can be increased and the concentration

of any compound below the site of action can be decreased using the fumonisin or fumonisin analog. However, the amounts of various compounds of the pathway can depend on the time period after inhibition or their relationship to other related pathways. For example, a fumonisin can bind sphingosine-N-acyltransferase, which would increase the amount of sphingosine by preventing the conversion back to ceramide and a fumonisin can also bind ceramide synthase (sphinganine-N-acyltransferase), which would decrease the amount of sphingosine by decreasing the amount of ceramide which can be converted to sphingosine. Thus, the fumonisin can cause both the increase and/or decrease of sphingosine, depending on which pathway is dominant. Such increases or decreases at various times after fumonisin ingestion can be routinely determined by methods utilized herein.

"Contacting the cell" as used herein means the fumonisin is administered in such a way that the fumonisin can enter the cell and affect the sphingolipid biosynthetic pathway within the cell. As shown below, the cell can be in a human or a nonhuman animal. Such in vivo activity is not only shown, but would be expected, because the nature of the sphingolipid metabolism would not differ fundamentally in vivo.

"Metabolism altering amount" as used herein means a quantity of a fumonisin capable of effecting a change in the sphingolipid metabolism in cells. Naturally, this amount can vary depending on the environment in which the cells are contained. For in vivo administration, the precise quantity of the fumonisin to elicit the desired effect can be determined by standard administration and monitoring until optimal dosage is determined. Such amounts can vary from subject to subject depending on size and condition of the subject.

As discussed above, the invention also provides a method of treating an abnormal condition in a subject associated with an alteration in sphingolipid metabolism. This method comprises administering a fumonisin, or an analog thereof, to the subject in a metabolism altering amount. The subject can be a human or a nonhuman animal and the abnormal condition can be caused by numerous disorders in sphingolipid metabolism. For example, the condition can be an excess of sphingosine resulting in Neimann-Picks syndrome, Tay-Sachs disease, a neoplastic condition or toxicity. In a given condition, the effects of fumonisin may be complex. For example, in a neoplastic condition, the fumonisin can, due to its structural similarity to sphingosine, prevent the formation of a sphingolipid required for growth of the cells and can also act as an inducer of differentiation and thus treat the neoplastic condition.

The invention also provides a method of treating an abnormal condition in a subject associated with the ingestion of a fumonisin or fumonisin analog which results in the depletion of a sphingolipid in the subject. This method comprises adding an amount of the sphingolipid to the subject sufficient to treat the condition. As can be seen by the pathway set forth in the figures, in general, compounds that occur in the biochemical pathway of sphingolipids after sphinganine can be depleted if sphinganine is not converted to dihydroceramide due to a fumonisin. Thus, adding the depleted compound or alternate compounds bypasses the blocked step. Similarly, fumonisins can bind ceramide synthase to prevent the conversion of sphingosine to ceramide and lead to an increase in sphingosine or a decrease in ceramide. Thus, adding the depleted compound or alternate compounds can also bypass this blocked step. Such conditions which can be effectively treated by this method can be determined by administering the compound to subjects suspected of

suffering such conditions. Likewise, an administration regimen can be optimized by routine testing.

Also provided is a method of treating an  
5 abnormal condition in a subject associated with the  
ingestion of a fumonisin or a fumonisin analog which  
results in the accumulation of a sphingolipid comprising  
adding an amount of an inhibitor of the sphingolipid to  
the subject sufficient to treat the condition. This  
10 method can be effective since compounds prior to  
dihydroceramide, especially sphinganine, can accumulate if  
sphinganine is not converted to dihydroceramide.  
Likewise, compounds such as sphingosine can accumulate if  
sphingosine is not converted to ceramide. Regimens can be  
15 determined as discussed above.

In treating an abnormal condition, the amount of  
fumonisin, or an analog thereof, which is administered can  
vary. Preferably the amount is between about 5 and 500  
20 mg, especially between about 25 and 75 mg when fumonisin B<sub>1</sub>  
or B<sub>2</sub> is utilized or an analog with a similar activity.  
The compounds according to the present invention are  
included in the pharmaceutically acceptable carrier in an  
amount sufficient to exert a therapeutically useful effect  
25 without exhibiting adverse toxic effects on the patient  
treated. Pharmaceutically compatible binding agents  
and/or adjuvant materials may also be included as part of  
the composition. The active materials can also be mixed  
with other active materials that do not impair the desired  
30 action and/or supplement the desired action. In general,  
the ratio of the fumonisin or the analog to the carrier is  
determined by the rate of administration and can be  
optimized using routine procedures.

35 It will be appreciated by those skilled in the  
art that the effective amount of a compound or formulation  
containing the compound required to treat an individual

will vary depending on a number of factors, including whether the fumonisin or the analog is administered, the route of administration, the nature of the condition being treated and the age and condition of the patient. The  
5 desired dose may be given in a single dose or as divided doses administered at appropriate intervals, such as two, three, four or more sub-doses per day. Thus, these compounds or their pharmaceutically acceptable derivatives can be conveniently administered by a convenient route of  
10 administration, such as parenteral, including intramuscular, subcutaneous and intravenous; oral; rectal; nasal; vaginal or by inhalation.

The invention also provides a composition  
15 comprising a fumonisin, or an analog thereof, in a pharmaceutically acceptable carrier. The carrier can be any carrier suitable for administration to a subject, for example, buffered saline. The fumonisin, or an analog thereof, can be present in an amount between 5 and 500 mg.  
20 Especially effective is an amount between 25 and 75 mg.

The invention also provides a method of detecting the consumption of a fumonisin or a fumonisin analog in a subject comprising (A) detecting, in a sample  
25 from the subject, the state of the metabolic pathway of sphingolipids and (B) comparing the state of the biosynthetic pathway to that of a normal subject, the presence of a change in the state of the biosynthetic pathway indicating the consumption of a fumonisin. The  
30 change in the metabolic pathway can, for example, be an increase in sphinganine or a decrease in a compound following sphinganine in the pathway or an increase in sphingosine. The discovery of the fact that fumonisins act on the sphingolipid biosynthetic pathway allows for  
35 easy diagnostics to be established based on pathway changes in a subject such as a horse or a human. This method provides a means to constantly monitor humans or

valuable farm animals to detect fumonisin or fumonisin analog intake, such as AAL toxins, before the fumonisin or analog causes a lethal effect.

5           A method of detecting the presence of a fumonisin or fumonisin analog contamination in a sample from a food or feed is also provided. The method comprises detecting a reaction of the metabolic pathway of sphingolipids, the presence of the reaction indicating the  
10 presence of a fumonisin contamination. For example, the reaction can be the prevention of the conversion of sphinganine, or an analog thereof, to dihydroceramide or an analog thereof, or the conversion of sphingosine, or an analog thereof, to ceramide, or an analog thereof, by  
15 ceramide synthase. However, again based on the core knowledge of the effect of a fumonisin on sphingolipid biosynthesis, related means of detecting the fumonisin can be established. The invention also provides a method of detecting the presence of a fumonisin contamination in a  
20 sample from a food comprising detecting a reaction of the metabolic pathway of sphingolipids, the presence of the reaction indicating the presence of fumonisin contamination. For example, the reaction is the conversion of sphingosine to ceramide or an analog thereof  
25 by ceramide synthase.

          Finally, the invention provides a method of diagnosing an abnormal condition in a subject associated with an alteration in sphingolipid metabolism comprising  
30 detecting the state of the metabolic pathway of sphingolipids in a subject and comparing the state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the presence of an abnormal condition. For  
35 example, an increase in sphinganine can indicate increased risk of esophageal cancer. Such a change can be detected by the following methods listed below, and abnormal

conditions other than esophageal cancer can be determined by using such methods. The conditions can result from an ingestion of a fumonisin or a fumonisin analog such as AAL toxins and include, for example, neoplastic conditions, toxicity, Neimann-Picks syndrome and Tay-Sachs disease.

#### EXPERIMENTAL PROCEDURES

All compounds listed in this application are commonly used and available and any abbreviation utilized is readily known to the skilled artisan.

#### Inhibition of Ceramide Synthase Activity in Rat Liver Microsomes and Reduced Conversion of [<sup>3</sup>H] Sphingosine to [<sup>3</sup>H] Ceramide by Intact Hepatocytes

Materials--Fumonisin B<sub>1</sub> and B<sub>2</sub> were purchased from Division of Food Sciences and Technology, CSIR, Pretoria, South Africa. Tissue culture media were purchased from Gibco (Grand Island, NY) and collagenase (Type IV), collagen (Type III), and palmitoyl-CoA were from Sigma (St. Louis, MO). Matrigel (from Engelbreth-Holm-Swarm (EHS) mouse tumor) were obtained from Collaborative Research Inc. (Bedford, MA). The [2-<sup>14</sup>C] serine and the [<sup>3</sup>H]sphingosine (prepared by catalytic exchange) were from New England Nuclear (Boston, MA). The sphingolipid standards were purchased from Sigma, or prepared synthetically (21).

Hepatocyte culture--Hepatocytes were prepared by a collagenase perfusion method, as known in the art as described in (22), from male Sprague-Dawley rats (125 to 200 g) fed a chow diet (Ralston Purina, St. Louis, MO) ad libitum. The hepatocytes were isolated using carefully aseptic procedures and plated in 60 mm tissue culture dishes coated with collagen for short term (< 24 h) or with Matrigel for longer term (3 to 4 d) experiments. After plating for 4 h, the medium was changed to 2 ml of DMEM (with 3.7 g/L NaHCO<sub>3</sub>) containing 10 µg/ml of insulin,

6.1 g/L of penicillin, 10 g/L of streptomycin sulfate, and varying concentrations of fumonisins (added from a 1 mM solution in Delbecco's phosphate buffered saline). The cells were maintained in a tissue culture incubator at 37° C and an atmosphere of 5% CO<sub>2</sub>; the medium was changed every 24 h. Cell viabilities were assessed by the ability of the cells to exclude 0.1% trypan blue, and were greater than 90%.

- 10 Lipid analyses--The de novo biosynthesis of sphingosine was measured, as known in the art as described in (23,24). Briefly, cells that had been exposed to fumonisins for 0 to 4 d were changed to new medium containing 10 µCi of [<sup>14</sup>C]serine (25 mCi/mmol) in 2 ml of serine-free DMEM
- 15 (Gibco) in the presence or absence of fumonisin. After incubation for 2 or 16 h, they were scraped from the dishes, 25 µg of carrier sphingosine and sphinganine were added, and the lipids were extracted and acid hydrolyzed to liberate the free long-chain bases using conditions
- 20 that give optimal hydrolysis with minimal decomposition of the labile long-chain bases, as known in the art as described in (23-25). The sphinganine and sphingosine were separated by thin-layer chromatography on silica gel H (Brinkman) plates developed with CHCl<sub>3</sub>:methanol:2 N
- 25 NH<sub>4</sub>OH (40:10:1, v/v/v) and the radiolabelling profile (shown in Fig. 2) was determined by radiometric scanning of the plates with a Bioscan System 200 Imaging Scanner. Sphingosine and sphinganine were visualized using
- 30 ninhydrin, which also revealed any acid decomposition products, which migrate as a ninhydrin-positive material near the solvent front (when seen, the data were not considered reliable). The appropriate regions of the chromatoplate were scraped, placed in scintillation vials, and 0.2 ml of water and 4 ml of a detergent based
- 35 scintillation cocktail were added. After several hours, the samples were counted with the appropriate corrections for quenching. In our experience (23,24,26,27), these

procedures give a good representation of the total amount of label in the long-chain base moieties of cellular sphingolipids.

5           To measure the relative activity of ceramide synthase in intact hepatocytes, the cells were incubated with 1  $\mu$ M fumonisin B<sub>1</sub> for 1 h, then 1  $\mu$ Ci of [<sup>3</sup>H]sphingosine was added and the cells were incubated for varying times. The [<sup>3</sup>H]sphingosine was freshly purified  
10 because it decomposes rapidly to a material with an R<sub>f</sub> similar to that of ceramides on TLC. The [<sup>3</sup>H]sphingosine was diluted to 1 Ci/mmol and applied to a small silica gel column (Unisil, Clarkston, IL) in chloroform. The column was washed with 10-column volumes of chloroform, the  
15 [<sup>3</sup>H]sphingosine was eluted with methanol and the purity confirmed by TLC. The [<sup>3</sup>H]sphingosine was transferred to a small test tube, the solvent was evaporated under N<sub>2</sub>, a small volume of culture medium was added immediately, and the tube was sonicated for a few minutes using a bath-type  
20 sonicator. Aliquots of this solution were added to the cells, and at the end of the specified incubation period the cells were scraped from the dish, 25  $\mu$ g of unlabelled ceramide carrier was added, and the lipids were extracted as described above. The [<sup>3</sup>H]ceramides were separated from  
25 [<sup>3</sup>H]sphingosine using silica gel H TLC plates developed with diethyl ether:methanol (99:1, v/v), visualized with I<sub>2</sub> vapor, and the amount of radiolabel was determined by scintillation counting.

30           Mass measurements of the long-chain bases were conducted by HPLC, as is known in the art as previously described in (28), with C20-sphinganine as an internal standard. To quantitate total sphingolipids, the extracts were acid hydrolyzed before preparing the samples for HPLC  
35 and corrected, if necessary, for any losses during hydrolysis or extraction by spiking replicate samples with a known amount of ceramide or sphingomyelin.

In vitro assays of serine palmitoyltransferase and ceramide synthase. A microsomal fraction was isolated from rat liver and assayed for serine palmitoyltransferase, as is known in the art as described in (24,29), and ceramide synthase, as is known in the art as described in (30), in the presence of varying concentrations of fumonisin B<sub>1</sub>. The assay mixture for ceramide synthase contained 1  $\mu$ M [<sup>3</sup>H]sphingosine, 25 mM potassium phosphate buffer (pH 7.4), 0.5 mM dithiothreitol, 200  $\mu$ M palmitoyl-CoA, and approximately 0.2 mg of microsomal protein in a total volume of 0.1 ml, which were found to be optimal assay conditions. The reaction was initiated by adding palmitoyl-CoA and, after incubation at 37° C for 15 min, the products were extracted, resolved by TLC, and quantitated as described above. Background counts were subtracted using data from identical assays that omitted palmitoyl-CoA.

Other methods--The incorporation of radiolabel into other lipids was determined by separating the phospholipids by TLC using silica gel H plates developed with CHCl<sub>3</sub>:methanol:formic acid:water (56:30:2:1, v/v/v/v), visualization of the spots and standards with I<sub>2</sub> vapor, and quantitation by scintillation counting. The amount of label in fatty acids was estimated using samples that had been incubated with 0.1 M KOH in methanol for 1 h at 37° C and separated using the ceramide TLC system because the methyl esters migrate near the solvent front under these conditions.

Results--Rat hepatocytes were selected as a model for the effects of fumonisins because F. moniliforme culture materials, now known to contain the cancer promoting fumonisin B<sub>1</sub> (9,15), are hepatotoxic and hepatocarcinogenic in the rat (4,10,31). Furthermore, sphingosine biosynthesis de novo by rat hepatocytes is relatively easy

to follow using [ $^{14}\text{C}$ ]serine, and proceeds via the reactions shown in Fig. 2 (24) like in other cells (23,32).

Fumonisin B<sub>1</sub> (1  $\mu\text{M}$ ) caused an almost complete inhibition of [ $^{14}\text{C}$ ]sphingosine formation by hepatocytes (Fig. 2 and 3). Similar inhibition occurred when [ $^{14}\text{C}$ ]serine and fumonisin B<sub>1</sub> were added together for short term (2 h) or overnight (16 h) incubations and when the cells were incubated overnight with fumonisin before adding [ $^{14}\text{C}$ ]serine (Fig. 3A, the 16 h + 2h group). Hence, fumonisin B<sub>1</sub> appears to act fairly quickly, and the inhibition is persistent. The IC<sub>50</sub> for inhibition of [ $^{14}\text{C}$ ]serine incorporation into [ $^{14}\text{C}$ ]sphingosine was approximately 0.1  $\mu\text{M}$  for fumonisin B<sub>1</sub> (Fig. 3B). A similar degree of inhibition was obtained with fumonisin B<sub>2</sub> (Fig. 3A), another mycotoxin often produced in substantial amounts by *F. moniliforme* (10).

In contrast, there was no reduction in the radiolabelling of phosphatidylserine, phosphatidylethanolamine, or phosphatidylcholine from [ $^{14}\text{C}$ ]serine (Table 1), nor in the mass of these phospholipids under conditions where sphingolipid labelling (Fig. 2 and 3) and mass (Table 1) were reduced significantly. Fatty acid biosynthesis from [ $^{14}\text{C}$ ]acetic acid was not altered (Table 1).

TABLE 1

Effects of Fumonisin B<sub>1</sub> on selected lipids of rat hepatocytes<sup>a</sup>

Parameter <sup>a</sup>	LM Fumonisin B <sub>1</sub>		
	0	1	10
A. Radiolabelling	(Dpm/mg protein $\times 10^{-3}$ ) Mean $\pm$ SD		
Phosphatidylethanolamine	103 $\pm$ 8.3	163 $\pm$ 4.4*	153 $\pm$ 10*
Phosphatidylserine	44.9 $\pm$ 9.5	48.8 $\pm$ 2.9	52.3 $\pm$ 3.6
Phosphatidylcholine	2270 $\pm$ 226*	2640 $\pm$ 264	2740 $\pm$ 196*

Parameter <sup>a</sup>	$\mu\text{M}$ Fumonisin B <sub>1</sub>		
	0	1	10
Base labile fatty acids <sup>b</sup>	2055 $\pm$ 261	2075 $\pm$ 54	2075 $\pm$ 103
B. Mass measurements <sup>c</sup>	(nmol/mg protein) Mean $\pm$ SD		
Phosphatidylethanolamine	44.1 $\pm$ 2.9	44.9 $\pm$ 1.4	44.4 $\pm$ 0.9
Phosphatidylserine	13.8 $\pm$ 2.8	15.5 $\pm$ 2.6	12.3 $\pm$ 1.9
Phosphatidylcholine	118 $\pm$ 3.6	105 $\pm$ 1.8	112 $\pm$ 3.4
Total sphingolipids	8.9 $\pm$ 0.9	6.7 $\pm$ 0.3 <sup>*</sup>	6.5 $\pm$ 0.7 <sup>*</sup>

- <sup>a</sup> Hepatocytes were incubated for 16 h with [<sup>14</sup>C]serine and the concentrations of fumonisin B<sub>1</sub> shown using the conditions described in Fig. 2. The lipids were extracted, separated by thin-layer chromatography, and quantitated as described in the text.  
<sup>b</sup> The groups that are significantly different (P < 0.05) from the control (no fumonisin) group are designated by asterisks.  
<sup>c</sup> Determined after incubation with 10  $\mu\text{Ci}$  of [<sup>14</sup>C]acetic acid.  
<sup>d</sup> Determined by phosphate analyses (27) with the exception of the total sphingolipids, which were estimated by acid hydrolysis of the lipid extracts and analysis of the amount of sphingosine by HPLC (28).

Hence, the inhibition of sphingolipid biosynthesis does not appear to be due to the inability of the cells to take up [<sup>14</sup>C]serine and to incorporate it into lipids in general, nor to affect the ability of the cell to form the other biosynthetic precursors (i.e., fatty acids).

Although de novo sphingolipid biosynthesis was completely blocked by 10  $\mu\text{M}$  fumonisin B<sub>1</sub>, there was only a slight reduction in the mass of total sphingolipids after 1 d (Table 1). This is probably due to the generally slow turnover of sphingolipids (32). A greater effect was seen when the cells were plated on Matrigel to allow incubation with 1  $\mu\text{M}$  fumonisin B<sub>1</sub> for 4 d, which reduced the level of total sphingolipids by about half (i.e., from 4.6  $\pm$  0.7 nmol/dish to 2.1  $\pm$  0.1 nmol/dish). There was no decrease in the number of viable cells despite treatment with 1  $\mu\text{M}$  fumonisin for 4 d.

There are several potential sites at which fumonisins might affect sphingosine metabolism (Fig. 2); hence, these were investigated further. Fumonisins do not appear to act at the first step of this pathway because even a fairly high concentration (25  $\mu$ M) fumonisin B<sub>1</sub> did not reduce the activity of serine palmitoyltransferase in vitro (i.e., the activities in the presence and absence of 25  $\mu$ M fumonisin B<sub>1</sub> were  $88 \pm 3$  and  $61 \pm 15$  pmol 3-ketosphinganine formed/min/mg of microsomal protein, respectively). Furthermore, treatment of hepatocytes with fumonisin B<sub>1</sub> followed by assays of this enzyme in disrupted cells revealed no inhibition (i.e., the activities were  $7.7 \pm 0.2$  and  $8.2 \pm 0.8$  pmol/min per mg of cellular protein in the presence and absence of 2.5  $\mu$ M fumonisin B<sub>1</sub>, respectively). Inhibition at the second step of the pathway is also unlikely because 3-ketosphinganine was not seen to accumulate (Fig. 2), and there was no reduction in the formation of [<sup>14</sup>C]sphinganine.

Fumonisins do inhibit at the step where [<sup>14</sup>C]sphinganine is converted to N-acyl[<sup>14</sup>C]sphinganine because the amount of radiolabel in [<sup>14</sup>C]sphinganine increased when hepatocytes were treated with fumonisin B<sub>1</sub> (Fig. 4A). This was accompanied by an increase in the mass of free sphinganine (Fig. 4B and C); when hepatocytes were incubated with 1  $\mu$ M fumonisin B<sub>1</sub> for 4 d, sphinganine increased 110 fold (i.e., to  $1499 \pm 18$  pmol/dish compared to  $13.6 \pm 0.4$  pmol/dish for the control). There was only a small reduction in the amount of free sphingosine within the first 2 h (Fig. 4B); however, free sphingosine decreased significantly after 4 d (i.e., to  $52 \pm 1$  pmol/dish compared to  $233 \pm 14$  pmol/dish for the control). These findings are consistent with the view that the free sphingosine found in hepatocytes is not an intermediate of the de novo biosynthetic pathway (23,24) (hence, will be affected little by short term treatment with fumonisin B<sub>1</sub>) but arises from the turnover of complex sphingolipids

(27,32) and would, therefore, be most affected when there is a decrease in total sphingolipids due to longer term exposure to these compounds.

5           Inhibition at this step of the pathway was demonstrated directly by in vitro assays of ceramide synthase, which has been reported to acylate both sphinganine and sphingosine (30) (Fig. 5) and by following the conversion of [<sup>3</sup>H]sphingosine to [<sup>3</sup>H]ceramide by intact  
10 cells (Fig. 4D). The apparent IC<sub>50</sub> for inhibition of this activity in vitro was approximately 0.1 μM for fumonisin B<sub>1</sub>, but the inhibition may be biphasic (Fig. 5). All together, these findings demonstrate that the inhibition of ceramide synthase accounts for the disruption of de  
15 novo sphingolipid biosynthesis by fumonisins, although these compounds may have additional effects on other enzymes of sphingolipid metabolism.

          The structural basis for this inhibition is due  
20 to similarities between the fumonisins and long-chain (sphingoid) bases (Fig. 1), which likely allow them to be recognized as substrate (or transition state or product) analogs by ceramide synthase. The absence of a hydroxyl group at carbon 1 may alter their orientation in the  
25 active site of this enzyme and preclude acylation or, if acylated, result in an inhibitory ceramide that cannot be removed by addition of a sphingolipid head group at that position. As shown in Fig. 1, the lack of a hydroxymethyl group at position 1 is shared by a number of other  
30 fumonisin-like compounds, such as the host-specific phytotoxins produced by another fungus, Alternaria alternata f. sp. lycopersici (33); hence, more naturally occurring inhibitors of this pathway exist. Data on the Alternaria toxins (AAL toxins) shown in Fig. 1  
35 demonstrates inhibition similar to that of fumonisins (Fig. 6). Specifically, when Alternaria toxins were added to hepatocytes, there was a dose-dependent reduction in

the formation of sphingolipids. In other experiments (not shown) we have also found that Alternaria toxins (AAL toxins) inhibit ceramide synthase in vitro. These compounds are also unable to follow the usual pathway of long-chain base catabolism, which proceeds via phosphorylation at position 1 (32), and this may contribute to the persistence of the inhibition.

These findings with rat hepatocytes provide the first identification of a biochemical target for the action of fumonisins, and demonstrate that inhibition of de novo sphingolipid biosynthesis in vitro may underlie the hepatotoxicity and hepatocarcinogenicity of this mycotoxin in vivo. The hepatic levels of fumonisins under these conditions are not known; however, if all the fumonisin given in feeding studies with rats (1 to 10 mg) (3-5,31) was distributed uniformly in the body, the concentrations could be between 10 and 100  $\mu\text{M}$ . This is surely an over- (or under-) estimation of the amount that reaches liver in vivo, but certainly considerably higher than the  $\text{IC}_{50}$  for inhibition of sphingolipid biosynthesis by hepatocytes (0.1  $\mu\text{M}$ ). In other studies, we have noted a 10 and 35% reduction in [ $^{14}\text{C}$ ]sphingosine biosynthesis by hepatocytes isolated from two rats given fumonisin B<sub>1</sub> (5 mg/200 g body weight) by gavage for just 2 days. There was also a pronounced reduction in the ratio of free [ $^{14}\text{C}$ ]sphingosine to [ $^{14}\text{C}$ ]sphinganine from  $2.6 \pm 0.14$  (a typical ratio for control hepatocytes) to  $0.5 \pm 0.1$ .

Disruption of this pathway is an attractive mechanism for the pathological effects of fumonisins since sphingolipids are involved in regulating various aspects of cell growth, differentiation, and transformation (18-20). For example, the degeneration of neuronal cells seen in equine leucoencephalomalacia can be due to inhibition of sphingolipid biosynthesis because brain contains high levels of sphingolipids (17). Also, an accumulation of

sphinganine in cells exposed to fumonisins can lead to cell death since long-chain bases can be highly cytotoxic (34,35), or to cell proliferation since these compounds are mitogenic to some cell types (36) and affect diverse cell systems (20), including protein kinase C (37), the epidermal growth factor receptor (38), the Na<sup>+</sup>/K<sup>+</sup> ATPase (39) and phosphatidic acid phosphohydrolase (40), inter alia. Thus, although toxic, fumonisins (or related compounds) can be therapeutically useful in diseases where defects in sphingolipid turnover cause cells to accumulate high levels of sphingolipids.

Alteration of serum sphingolipids upon dietary exposure of ponies to fumonisins, mycotoxins produced by *Fusarium moniliforme*

Materials--Corn screenings were ground in a Romer Mill (Romer Labs, Chesterfield, Missouri) and mixed thoroughly. Samples were taken from each lot and analyzed for fumonisins by high-performance liquid chromatography (HPLC) and thin-layer chromatography as is known in the art as previously described in (15). If the amounts of fumonisin B1 showed greater than 10% variation (relative standard deviation in 8 samples from each 25 kg lot), the lot was mixed, sampled, and analyzed a second time or until variance was less than 10%. Using the mean fumonisin B<sub>1</sub> level, individual rations were prepared daily by adding the corn screenings to pellets (NADC Horse Ration, Code 560, Purina Mills, St. Louis, Missouri) and molasses (Promolas Easy Mixer Supreme, Pacific Molasses Co., San Francisco, California) to yield the fumonisin concentrations cited in the text. In general, the ration contained 60% pellets, 10% molasses, and 30% corn screenings. The control diet consisted of pellets plus molasses.

All portions of the diet were subjected to general screens for toxicants by gas chromatography/mass

spectroscopy and inductively coupled plasma spectroscopy, and assayed for chlorinated hydrocarbon pesticides, organophosphate pesticides, carbamate pesticides, aflatoxins, zearalenol, T-2 toxin, diacetoxyscirpenol, deoxynivalenol, 15-acetyl deoxynivalenol, fusarenone-x, zearalenone, HT-2 toxin, T-2 tetrol, sterigmatocystin, cyclopiazonic acid, ochratoxin A, gliotoxin, sporodesmin, and griseofulvin. In addition, the hay, molasses, and pellets were tested for fumonisin B1 and B2.

10

Feeding protocols--Clinically normal ponies of varying age and sex were conditioned on the control diet for 21 days prior to the trial. Horse 341 was a 6 year old gelding (173-193 Kg), 299 was a 12 year old mare (205-215 Kg), 164 was a 12 year old mare (206-290 Kg) and 166 was a 16 year old mare (143-164 Kg). During the conditioning period and throughout the trial, all ponies received alfalfa hay by free choice. The test groups were fed varying levels of fumonisin (15 to 44 ppm) for varying lengths of time. The individual unconsumed rations were measured daily; at certain times, the ponies consumed variable portions of the rations, and these have been indicated in the figures.

15  
20

Analysis of serum long-chain bases--Blood was drawn approximately twice a week, centrifuged to obtain serum, and aliquots were frozen for analyses of free sphingosine and sphinganine by HPLC as is known in the art as described in (28). To quantitate total sphingolipids in some samples, the extracts were acid hydrolyzed before preparing the samples for HPLC.

25  
30

Clinical chemistry, evaluation, and tissue collection--The following clinical chemistry parameters were also analyzed with blood: total bilirubin, direct bilirubin, urea nitrogen, alkaline phosphatase, AST/SGOT, creatine kinase, gamma glutamyl transaminase, and bile acids. The animals were observed intermittently throughout each day and

35

behavior changes were noted. Animals that were euthanized or died underwent a routine necropsy, and brain, liver, and kidney were prepared for microscopic study.

- 5 Results--Analyses of sera from three ponies that had not been exposed to fumonisin contaminated feed produced HPLC profiles like the one shown in Table 2.

TABLE 2

PEAK NO.	TIME	AREA	CONC
1	1.088	20366	0.0898
2	1.733	22118978	97.5714
3	2.413	134152	0.5918
4	2.944	94677	0.4176
5	3.971	4455	0.0197
6	4.2	2677	0.0118
7	4.47	773	0.0034
8	5.21	2416	0.0107
9	5.483	2141	0.0094
10	6.283	11185	0.0493
11	8.28	3517	0.0155
12	13.688	274192	1.2095
TOTAL		22669520	100

Sphingosine elutes at 6.3 min and, for this sample, sphinganine (at 8.3 min) can also be seen clearly. In some instances, the amount of sphinganine was too low to detect above background. The compound eluting at 13.7 min is the internal standard (C20-sphinganine) that is added to aid extraction and quantitation of the long-chain bases (28).

- 35 Data for sera collected from three ponies at intervals of 2 weeks to 9 months are given in Table 3.

TABLE 3

Levels of free long-chain bases in sera from four ponies given feed thought to be free of contamination by fumonisins.

Days after initial sampling	Sphingosine pmol/ml	Sphinganine pmol/ml	Ratio Sa/So
Pony #299			
0	46.8 $\pm$ 1.2	13.6 $\pm$ 0.4	0.29
14	39.3 $\pm$ 1.6	10.9 $\pm$ 1.2	0.28
65	107 $\pm$ 18	22.9 $\pm$ 6.0	0.19
248	59.3 $\pm$ 6.0	16.4 $\pm$ 6.4	0.26
Pony #164			
0	118 $\pm$ 5	22.6 $\pm$ 4.6	0.19
2	97 $\pm$ 10	32.4 $\pm$ 8.0	0.32
7	63 $\pm$ 1	27.3 $\pm$ 1.4	0.43
22	42 $\pm$ 2	11.7 $\pm$ 4.0	0.26
Pony #166			
0	82 $\pm$ 24	22.2 $\pm$ 1.8	0.25
2	33 $\pm$ 1	20.7 $\pm$ 0.2	0.63
7	54 $\pm$ 1	20.8 $\pm$ 2.0	0.40
22	43 $\pm$ 4	13.7 $\pm$ 0.6	0.32

Sphingosine is the predominant free long-chain base in serum from all ponies. The mean  $\pm$  SD for all of the analyses (n=12) were: 65  $\pm$  29 pmol sphingosine/ml serum and 19.5  $\pm$  6.5 pmol sphinganine/ml serum. There was some variability in the amounts of these compounds over time, although this was seen less in sphinganine than sphingosine; furthermore, the sphinganine to sphingosine ratio (0.32  $\pm$  0.12) was fairly constant. This latter parameter may be useful because these compounds are sometimes difficult to extract efficiently; hence, a ratio of two structurally related species (i.e., sphinganine and

sphingosine versus the C20-sphinganine standard or sphinganine versus sphingosine) will be more accurate than absolute measurements of the mass of a single compound.

5 Table 4 illustrates a serum sample from the same pony as in Table 2 after exposure to fumonisin-contaminated feed.

10

TABLE 4

PEAK NO.	TIME	AREA	CONC
1	1.091	23970	0.1095
2	1.733	21355228	97.5859
15 3	2.412	74417	0.3401
4	2.945	97222	0.4443
5	4.166	17641	0.0806
6	5.09	11076	0.0506
7	5.507	2952	0.0135
20 8	5.883	2220	0.0101
9	6.328	47332	0.2163
10	7.627	1052	0.0048
11	8.326	70389	0.3217
12	13.761	180023	0.8226
25 TOTAL		21883512	100

Differences in the HPLC profile are evident both on the magnitude of the peaks and the relative amounts of sphingosine and sphinganine. The levels of sphingosine and sphinganine are summarized in Table 5 for two ponies given 44 ppm fumonisin B1, a level that is often toxic and resulted in ELEM in both of these animals (pony 164 died after 10 days and pony 166 was euthanized on day 45).

TABLE 5

5 Levels of free long-chain bases in sera from two ponies given feed contaminated with fumonisin B1 at 44 ppm

Day of Trial	Sphingosine pmol/ml	Sphinganine pmol/ml	Ratio Sa/So	AST/SGOT Units
Pony #164 <sup>1</sup>				
-1	42 ± 2	11.7 ± 4.0	0.26	248
2	117 ± 7	70.2 ± 4.2	0.60	235
7	152 ± 13	253 ± 22	1.67	357
10	226 ± 20	283 ± 18	1.25	4000
Pony #166 <sup>2</sup>				
-1	43 ± 4	13.7 ± 0.6	0.32	210
2	43 ± 6	37.2 ± 0.2	0.87	199
7	66 ± 16	62 ± 8	0.95	215
10	92 ± 4	179 ± 8	1.92	1470
13	100 ± 8	174 ± 18	1.72	2080

- 20 <sup>1</sup> Pony was described as nervous and off feed from day 5; by day 9 was blind and down, and on day 10 had full clinical signs of ELEM and died that evening.
- 25 <sup>2</sup> Pony was described as lethargic from day 5; off feed from day 8; later put back on full feed and exhibited CNS signs; was euthanized on day 45.

By day 2, pony 164 exhibited elevations in sphingosine and sphinganine; however, the increase in sphinganine was greatest (6-fold compared to the level immediately prior to feeding fumonisin) and this was reflected in an increase in the ratio of sphinganine to sphingosine, which doubled. By day 7, sphinganine had increased 22-fold and sphingosine was 3.6-fold compared to the initial level. The pronounced increase in sphinganine over sphingosine gave a sphinganine to sphingosine ratio (1.67) that is unprecedented in any previous analyses of long-chain bases in mammalian systems--except our above studies of the effects of fumonisins on hepatocytes.

Pony 166 also showed an increase in sphinganine (2.7 fold), but not sphingosine, after only two days on contaminated feed, the earliest timepoint examined. By day 7, sphingosine and sphinganine were both elevated, but sphinganine had increased to the level of sphingosine. By day 10, pony 166 showed elevations in sphingosine (2-fold), sphinganine (13-fold), and AST/SGOT (7-fold) that indicate significant hepatic injury.

Another pony (#212) was initially given 44 ppm of fumonisin, but less was eaten because of variable consumption of the feed and because the fumonisin was withheld for two weeks. The results for this animal are shown in Fig. 7. As for the other two ponies, there was a rapid increase in free long-chain bases that slightly preceded the clinical signs of toxicity (i.e., elevated AST/SGOT). Within 2 days the sphingosine level had nearly doubled over the amount the day prior to administration of contaminated feed (i.e., from  $49.1 \pm 5$  pmol to  $147 \pm 5$  pmol); sphinganine was also elevated but the fold increase could not be calculated because sphinganine was not detectable in serum from this pony before the trial. By 7 days, sphingosine had increased another 2-fold, but sphinganine was 6.7 fold higher than the level at day 2, and now exceeded the level of sphingosine by 1.9 fold. After day 10 of the study, both sphinganine and sphingosine decreased, although the ratio remained elevated above that before exposure to fumonisin. The decrease was during the period where the pony consumed variable amounts of the contaminated feed (i.e., from day 5 through 31) and when the feed was withdrawn all together. The contaminated feed was provided again on day 45 and was consumed variably until termination of the study on day 97. Restoration of the fumonisin resulted in small increases in sphingosine and sphinganine, but most prominently in the sphinganine to sphingosine ratio of 2 to 3. This behavior suggests that serum sphingosine and

sphinganine, and most especially their ratio, increases after fumonisin exposure, returns to more normal levels upon removal of (or more variable consumption of) contaminated feed, and increases again when the animals  
 5 are reexposed to fumonisin in the diet.

The fourth pony (#341) was given lower amounts of fumonisin-contaminated feed as shown in Fig. 8. During the first 130 days at 15 ppm fumonisin B1, the levels of  
 10 free sphingosine and sphinganine fluctuated with no noticeable pattern (data not shown); however, when the data are expressed as the ratio of these compounds, there was a fairly consistent elevation over the initial value. Although the initial ratio is based on a single serum  
 15 sample at the start of the experiment, it was similar to that of the other animals studied.

When pony 341 was taken off the fumonisin between day 130 and 160, the ratio dropped to a level that  
 20 was below the starting level. Fumonisin feeding was resumed at 22 ppm on day 161, and there was a rapid increase in the sphinganine to sphingosine ratio, and the ratio declined again when the pony was taken off fumonisin between days 175 and 182. Reintroduction of 22 ppm  
 25 fumonisin B1 on day 182 was accompanied by a rapid increase in the ratio to  $>1.5$ , which culminated in a precipitous fall on day 235. Later that day the pony died with the symptoms of equine leucoencephalomalacia, which was later confirmed by biopsy. This final decrease in the  
 30 ratio was due to a greater than two-fold increase in sphingosine (i.e., from 163 to 418 pmol/ml between day 231 and 235, rather than to a reduction in sphinganine (which also increased from 256 to 532 pmol/ml).

35 The upper panel of Fig. 8 shows serum AST/SGOT of pony 341 over this period. The activities were essentially unaffected until between day 224 and 231.

Other markers of liver function were also unaltered until this period. Thus, changes in the free long-chain bases appeared much earlier (at least a month or more) before exposure to fumonisins was detectable by elevations in liver enzymes.

If the elevation in sphinganine is due to inhibition of de novo sphingolipid biosynthesis, this might also be reflected in a reduction in the amounts of more complex sphingolipids in serum. This possibility was examined with sera from several of the ponies as shown in Table 6.

TABLE 6

Levels of long-chain bases liberated from the total serum lipids upon acid hydrolysis to cleave more complex sphingolipids

Day of Trial	Sphingosine pmol/ml	Sphinganine pmol/ml	AST/SGOT units
	Total (-free)	Total (-free)	
	Pony 164		
-20	3400 $\pm$ 266 (ND)	203 $\pm$ 18 (ND)	270
-15	2670 $\pm$ 678 (2630)	139 $\pm$ 22 (127)	224
2	621 $\pm$ 99 (504)	169 $\pm$ 30 (99)	235
7	254 $\pm$ 32 (102)	156 $\pm$ 48 (0) <sup>2</sup>	357
10	2960 $\pm$ 585 (2740)	786 $\pm$ 234 (503)	4000
	Pony 166		
-22	3620 $\pm$ 452 (3580)	123 $\pm$ 23 (103)	215
-15	4430 $\pm$ 409 (4380)	93 $\pm$ 9 (70)	180
-1	2340 $\pm$ 694 (2290)	211 $\pm$ 69 (197)	210
2	1020 $\pm$ 313 (974)	131 $\pm$ 40 (94)	199
7	950 $\pm$ 154 (985)	206 $\pm$ 18 (144)	215
10	634 $\pm$ 192 (540)	212 $\pm$ 28 (34)	1470
13	1740 $\pm$ 150 (1640)	823 $\pm$ 54 (650)	2080

Day of Trial	Sphingosine pmol/ml	Sphinganine pmol/ml	AST/SGOT units
	Total (-free)	Total (-free)	
Pony 208			
-22	6940 $\pm$ 88 (6610)	267 $\pm$ 11 (235)	419
-15	4950 $\pm$ 163 (4750)	178 $\pm$ 3 (153)	327
-1	5540 $\pm$ 42 (5270)	218 $\pm$ 18 (279)	305
2	3490 $\pm$ 358 (3190)	387 $\pm$ 26 (107)	344
6	2390 $\pm$ 388 (2030)	718 $\pm$ 75 (60)	2130
10	4450 $\pm$ 10 (3460)	2040 $\pm$ 70 (200)	1240
13	15970 $\pm$ 1576 (15040)	9990 $\pm$ 379 (9604)	1010

10 The description of the ponies is given in the text and Table 3. Data is not given for a few of the days of feeding because there was too little sample available to conduct the analysis.

15 These values underestimate the contribution of free long-chain bases because they are somewhat unstable under the acid hydrolysis conditions.

For these analyses, the lipids were extracted and then hydrolyzed to liberate the free long-chain bases which were analyzed by HPLC. The results (Table 6) show that  
 20 the levels of total (complex) sphingolipids were reduced by 50 to 95% during the early times after feeding fumonisin, but that the levels increased again when there was also an elevation in hepatic enzymes. As discussed earlier, this increase may reflect the release of membrane  
 25 sphingolipids into circulation upon cell injury.

Since pony 164 was clearly undergoing rapid tissue injury (as reflected in the marked elevation in AST/SGOT by day 7), it is likely that the increase in  
 30 sphingosine was due to the turnover of sphingolipids in injured tissues. This is, again, consistent with a mechanism whereby a block at the level of acylation of newly synthesized sphinganine occurs as described above. That study showed that inhibition of ceramide synthase  
 35 results in accumulation of sphinganine as an intermediate

of de novo sphingolipid biosynthesis. The free sphingosine (and some sphinganine) occurs from the turnover of existing complex sphingolipids; hence, this will be affected somewhat as fumonisins inhibit the reacylation of this long-chain base. In both the magnitude and the speed with which changes appeared, the increase in serum long-chain bases was an earlier indicator of exposure to fumonisins than elevations in AST/SGOT for both of these ponies. Hence, changes in the sphinganine to sphingosine ratio can detect exposure of ponies to fumonisin by 1 to 2 months earlier than liver function tests.

#### Synthesis of Fumonisin and Fumonisin Analogs

The following more particularly describes the synthesis of fumonisin and fumonisin analogs (see Fig. 1), which are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art. Numeral references following a particular compound refer to the structures found in Fig. 9.

The synthesis of the fumonisin analog 2-amino-octadeca-3,5-diol from L-alanine methyl ester hydrochloride (1) is given below. Obviously, a particular fumonisin or other fumonisin analogs can be formed utilizing this general synthesis by the addition of the appropriate Grignard reagent to compound 4 and, if necessary, functionalization of oxygen or nitrogen atoms contained in that Grignard reagent at the appropriate time to attach mono- or polycarboxylate moieties to the tail of the compound. Ester or ceramide couplings of this type can be readily accomplished using a variety of reagents well-known to those skilled in the art. Furthermore, the X and Y substituents, as shown in the fumonisin analog of Fig. 1, can be added by methods known in the art.

Introduction of the V-substituent can be readily accomplished using a hydride opening of an epoxide (e.g., 6 of Fig. 9) to obtain V = H or an epoxide opening with a variety of oxygen nucleophiles to ultimately obtain V = OH. By controlling both the stereochemistry of the epoxidation (e.g., 5a → 6 of Fig. 9) and the regiochemistry of the subsequent epoxide opening with hydride or oxygen nucleophiles, the preparation of all possible variations of V and Y = H or OH can be achieved. Because the head group is likely to be an important factor in modulating the biological activity of the compound in question, modifications of this type may prove to be important.

L-Alanine methyl ester hydrochloride (1) (1.0 eq, 179.1 mmol, 25 gm) was dissolved in 500 ml of dry N, N-dimethylformamide (DMF) under a nitrogen atmosphere. Distilled triethylamine (2.5 eq, 447.2 mmol, 45.3 gm) and di-*t*-butyl dicarbonate ((BOC)<sub>2</sub>O) (1.1 eq, 197.4 mmol, 43 gm) were then added and the reaction mixture was heated and stirred at 60 °C for 1 hour and at room temperature for an additional 4 hours. The DMF was then evaporated in vacuo and the remaining residue was dissolved in ethyl acetate, cooled to 5 °C, washed with 10% citric acid, saturated NaHCO<sub>3</sub>, and brine, dried over anhydrous MgSO<sub>4</sub>, filtered, and the solvent was evaporated in vacuo. The N-BOC-protected ester 2 was purified via flash column chromatography and a colorless oil was obtained in 88% yield.

30

Ester 2 (1.0 eq, 49.3 mmol, 10 gm) was dissolved in dry toluene (400 ml) and cooled to -78 °C under a nitrogen atmosphere. Diisobutylaluminum hydride (DIBAL-H) (1.4 eq, 69.0 mmol) was then added slowly and the reaction monitored by TLC. After 3.5 hours, the reaction was quenched at -78 °C with ethanol and allowed to warm to room temperature. The turbid solution was filtered

through silica gel and the aluminum salts were thoroughly washed with ether. Rotary evaporation of the solvent yielded the product (3) (82% yield) as a white solid and the aldehyde was purified by flash column chromatography.

5

Aldehyde 3 (1.0 eq, 17.9 mmol, 3.1 gm) and triphenylphosphoranylidine acetaldehyde (2.2 eq, 39.4 mmol, 12.1 gm) were dissolved in 250 ml of dry benzene and refluxed under a nitrogen atmosphere for 2 hours. Benzene was evaporated in vacuo and the crude product (brown solid) was purified via flash column chromatography. The unsaturated aldehyde 4 was isolated in 72% yield and used immediately.

15

An excess of magnesium turnings was placed in a 3-neck round bottom flask and flame-dried under a vacuum. After cooling, 125 ml of ether was added followed by 1-bromotridecane (2.2 eq, 28.8 mmol, 7.6 gm) and the mixture was stirred under reflux for 24 hours. Aldehyde 4 (1.0 eq, 13.1 mmol, 2.6 gm) was dissolved in 100 ml of ether under a nitrogen atmosphere and cooled to 0 °C. The Grignard reagent was then cannulated into the aldehyde solution and allowed to warm up to room temperature for 2 hours. The reaction was then quenched with saturated NH<sub>4</sub>Cl solution and the organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The diastereomeric mixture of alcohols (5) were separated via flash column chromatography and isolated in 86% yield.

30

Allylic alcohol 5a (1.0 eq, 0.63 mmol, 240 mg) was dissolved in 10 ml CHCl<sub>3</sub> and 10 ml of 0.5M NaHCO<sub>3</sub>. meta-Chloroperbenzoic acid (1.1 eq, 0.69 mmol, 120 mg) was added slowly and the reaction was stirred overnight. The organic layer was then washed with brine, dried over MgSO<sub>4</sub> and concentrated in vacuo. The mixture of diastereomeric epoxides (6) were separated by flash column chromatography in 90% yield.

35

Epoxide 6a (1.0 eq, 72.5  $\mu$ mol, 30 mg) was dissolved in 5 ml of dry THF and cooled to 0 °C under a nitrogen atmosphere. Bis(2-methoxyethoxy)aluminum hydride (2.5 eq, 0.19 mmol) was then added and the reaction mixture was allowed to warm up overnight. The reaction was quenched with ethanol, filtered over celite and concentrated in vacuo to produce diol 7 in 76% yield after purification. Sodium triacetoxyborohydride can also be utilized to produce diol 7 at this step.


10

Carbamate 7 (1.0 eq, 124  $\mu$ mol, 50 mg) was dissolved in 25 ml of ethyl acetate and cooled to 0 °C under a nitrogen atmosphere. Dry HCL gas (> 3 eq) was bubbled through the solution and allowed to stir for 6 hours at 0 °C as determined by TLC. The reaction was then basified to pH 9 with 10%  $\text{NH}_4\text{OH}$  and the organic layer washed with brine, dried over anhydrous  $\text{MgSO}_4$ , and concentrated in vacuo. Flash column chromatography produced the amino diol 8 as a white solid in 78% yield.

20

With reference to the definition of fumonisin analogs given above, the Spacer Groups can be added to the various head groups in two different fashions. The first involves a Wittig (or Wadsworth/Emmons/Horner) olefination in which an ylide containing a terminal oxygen, nitrogen or carboxyl functional group is allowed to react with an aldehyde. Examples of the types of ylides used are given by the structure:

30



where  $n = 1 - 20$  (straight or branched chain and  $\text{X} = \text{O}$ -Protecting Group,  $\text{NH}$ -Protecting Group,  $\text{NR}$ -Protecting Group,  $\text{CO}_2\text{H}$  (Li)).

35

The second approach involves an acetylide addition to an aldehyde. The types of acetylides which are used are shown below:



where  $n = 1 - 20$  (straight or branched chain;  $X = O$ -Protecting Group,  $NH$ -Protecting Group,  $NR$ -Protecting Group (wherein  $R =$  a straight or branched chain  $C_1 - C_6$  alkyl),  $CO_2H(M)$ ; and  $M = Li, Na, K$ , etc. As used herein, "a Protecting group" refers to a moiety that provides protection for the corresponding alcohol or amide until deprotection is desired. This protection/deprotection process is well-known in the art as discussed in (41).

15 Fig. 10 shows various reaction schemes that can be employed to control the stereochemistry of the 2-aminopenta-3,5-diol head group during the synthesis of a fumonisin or fumonisin analog. Fig. 11 shows various  
20 reaction schemes that can be employed to control the stereochemistry of the aminotriol head groups present in Alternaria toxins or fumonisin analogs similar to Alternaria toxins.

25 Although the present processes have been described with reference to specific details of certain embodiments thereof, it is not intended that such details should be regarded as limitations upon the scope of the invention except as and to the extent that they are  
30 included in the accompanying claims.

## REFERENCES

1. Marasas, W. F. O., Nelson, P. E., and Toussoun, T. A.,  
5 Toxigenic Fusarium Species: Identity and  
Mycotoxicology. The Pennsylvania State University  
Press, University Park, PA (1984).
2. Kellerman, T. S., Marasas, W. F. O., Pienaar, J. G.,  
10 and Naude, T. W. (1972) Onderstepoort J. Vet. Res.  
39, 205-208.
3. Kriek, N. P. J., Kellerman, T. S., and Marasas, W. F.  
O. (1981) Onderstepoort J. Vet. Res. 55, 129-131.
- 15 4. Marasas, W. F. O., Kriek, N. P. J., Fincham, J. E.  
and van Rensburg, S. J. (1984) Int. J. Cancer 34,  
383-387.
5. K. A. Voss, R. D. Plattner, C. W. Bacon, and W. P.  
20 Norred (1990) Mycopathologia 112, 81-92.
6. Marasas, W. F. O. (1982) in Cancer of the Oesophagus,  
Vol. 1, (Pfeiffer, C. J., ed.) CRC Press, Boca Raton,  
pp. 29-40.
- 25 7. Lin, M., Lu, S., Ji, C., Wang, Y., Wang, M., Cheng,  
S., and Tian, G. (1980) in Genetic and Environmental  
Factors in Experimental and Human Cancer (Gelboin, H.  
V., ed.) Japan Sci. Soc. Press, Tokyo, pp. 139-148.
- 30 8. Yang, C. S. (1980) Cancer Res. 40, 2633-2644.
9. Bezuidenhout, C. S., Gelderblom, W. C. A., Gorst-  
allman, C. P., Horak, R. M., Marasas, W. F. O.,  
35 Spiteller, G., and Vleggaar, R. (1988) J. Chem. Soc.  
Comm. 743-745.
10. Voss, K. A., Norred, W. P., Plattner, R. D., and  
Bacon, C. W. (1989) Food Chem. Toxicol. 27, 89-96.
- 40 11. Sydenham, E. W., Gelderblom, W. C. A., Thiel, P. G.,  
and Marasas, W. F. O. (1990) J. Agric. Food Chem. 38,  
285-290.
- 45 12. Marasas, W. F. O., Kellerman, T. S., Gelderblom, W.  
C. A., Coetzer, J. A. W., Thiel, P. G., and van der  
Lugt, J. J. (1988) Onderstepoort J. Vet. Res. 55,  
197-203.
- 50 13. Harrison, L. R., Colvin, B., Greene, J. T., Newman,  
L. E., and Cole, J. R. (1990) J. Vet. Diagn. Invest.  
2, 217-221.
- 55 14. Gelderblom, W. C. A., Jaskiewicz, K., Marasas, W. F.  
O., Thiel, P. G., Horak, R. M., Vleggaar, R., and

- Kriek, N. P. J. (1988) Appl. Environ. Microbiol. 54, 1806-1811.
- 5 15. Ross, P. F., Rice, L. G., Plattner, R. D., Osweiler, G. D., Wilson, T. M., Owens, D. L., Nelson, H. A. and Richard, J. L. (1991) Mycopathologia (in press)
16. Hakomori, S.-I. (1981) Ann. Rev. Biochem. 50, 733-764.
- 10 17. Sweeley, C. C. (1985) In Biochemistry of Lipids and Membranes (D. E. Vance and J. E. Vance, eds.) Benjamin/Cummings Pub., Menlo Park, CA., Chapter 12.
- 15 18. Hannun, Y. A. and Bell, R. M. (1989) Science 243, 500-507.
19. Hakomori, S. -I. (1990) J. Biol. Chem. 265, 18713-18716.
- 20 20. Merrill, A. H., Jr. (1991) J. Biomemb. Bioenerget. 23, 83-104.
21. Merrill, A. H., Jr., Nimkar, S., Menaldino, D., Hannun, Y. S., Loomis, C., Bell, R. M., Tyagi, S. R., Lambeth, J. D., Stevens, V. L., Hunter, R., and Liotta, D. C. (1989) Biochemistry 28, 4360-4366.
- 25 22. Yao, Z. and Vance, D. E., (1988) J. Biol. Chem. 263, 2998-3004.
- 30 23. Merrill, A. H., Jr. and Wang, E. (1986) J. Biol. Chem. 261, 3764-3769.
- 35 24. Messmer, T. O., Wang, E., Stevens, V. L., and Merrill, A. H., Jr. (1989) J. Nutr. 119, 534-538.
25. Gaver, R. and Sweeley, C. C. (1966) J. Amer. Chem. Soc. 88, 3643-3647.
- 40 26. Medlock, K. A. and Merrill, A. H., Jr. (1988) Biochem. Biophys. Res. Commun. 157, 232-237.
27. Slife, C. W., Wang, E., Hunter, R., Wang, S., Burgess, C., Liotta, D. C., and Merrill, A. H. Jr. (1989) J. Biol. Chem. 264, 10371-10377.
- 45 28. Merrill, A. H., Jr., Wang, E. Mullins, R. E., Jamison, W. C. L., Nimkar, S., and Liotta, D. C. (1988) Anal. Biochem. 171, 373-381.
- 50 29. Williams, R. D., Wang, E., and Merrill, A. H., Jr. (1984) Arch. Biochem. Biophys. 228, 282-291.
- 55 30. Morrell, P. and Radin, N. S. (1970) J. Biol. Chem. 245, 342-350.

31. Jaskiewicz, K., van Rensburg, S. J., Marasas, W. F.,  
and Gelderblom, W. C. (1987) J. Natl. Cancer Inst.  
78, 321-325.
- 5 32. Merrill, A. H., Jr. and Jones, D. D. (1990) Biochem.  
Biophys. Acta 1044, 1-12.
33. Bottini, A. T., Bowen, J. R., and Gilchrist, D. G.  
(1981) Tetrahedron Lett. 22, 2723-2726.
- 10 34. Merrill, A. H., Jr. (1983) Biochem. Biophys. Acta  
754, 284-291.
- 15 35. Stevens, V. L., Nimkar, S., Jamison, W. C., Liotta,  
D. C., and Merrill, A. H., Jr. (1990) Biochem.  
Biophys. Acta 1051, 37-45.
- 20 36. Zhang, H., Buckley, N. E., Gibson, K., and Spiegel,  
S. (1990) J. Biol. Chem. 263, 76-81.
37. Hannun, Y. A., Loomis, C. R., Merrill, A. H., Jr. and  
Bell, R. M. (1986) J. Biol. Chem. 261, 12604-12609.
- 25 38. Faucher, M., Girones, N., Hannun, Y. A., Bell, R. M.,  
and Davis, R. J. (1988) J. Biol. Chem. 263, 5319-  
5327.
39. Oishi, K., Zheng, B. and Kuo, J. -F. (1990) J. Biol.  
Chem. 265, 70-75.
- 30 40. Jamal, Z., Martin, A., Gomez-Munoz, A. and Brindley,  
D. N. (1991) J. Biol. Chem. 266, 2988-2996.
- 35 41. Greene, T. W., Protecting Groups in Organic  
Chemistry, John Wiley and Sons, NYC, 1981.

What is claimed is:

1. A method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a purified  
5 fumonisin, or an analog thereof.
2. The method of Claim 1, wherein the alteration is effected by binding sphingosine-N-acyltransferase with the fumonisin, or an analog thereof.
- 10 3. The method of Claim 1, wherein the alteration is effected by binding ceramide synthase with the fumonisin, or an analog thereof.
- 15 4. The method of Claim 1, wherein the analog has a hydroxyl group at the first carbon.
5. The method of Claim 1, wherein the analog has a 2-aminopenta-3,5-diol head group.
- 20 6. The method of Claim 1, wherein the fumonisin is Fumonisin B<sub>1</sub>.
7. The method of Claim 1, wherein the fumonisin is  
25 Fumonisin B<sub>2</sub>.
8. The method of Claim 1, wherein the fumonisin analog is AAL toxin.
- 30 9. A method of treating an abnormal condition in a subject associated with an alteration in sphingolipid metabolism comprising administering a fumonisin, or an analog thereof, to the subject in a metabolism altering amount.

35

10. The method of Claim 9, wherein the subject is a human and the abnormal condition is caused by an excess of sphingosine.
- 5 11. The method of Claim 10, wherein the abnormal condition is selected from the group consisting of Neimann-Picks syndrome, Tay-Sachs disease, a neoplastic condition and toxicity.
- 10 12. The method of Claim 9, wherein the amount of fumonisin, or an analog thereof, which is administered is between 5 and 500 mg.
13. The method of Claim 9, wherein the amount of  
15 fumonisin, or an analog thereof, which is administered is between 25 and 75 mg.
14. The method of Claim 9, wherein the analog has a hydroxyl group at the first carbon.
- 20 15. The method of Claim 9, wherein the analog has a 2-amino-3,5-diol head group.
16. The method of Claim 9, wherein the fumonisin is  
25 Fumonisin B<sub>1</sub>.
17. The method of Claim 9, wherein the fumonisin is Fumonisin B<sub>2</sub>.
- 30 18. The method of Claim 9, wherein the fumonisin analog is AAL toxin.
19. A composition comprising a fumonisin, or an analog thereof, in the form of a racemic mixture or a single  
35 isomer in a pharmaceutically acceptable carrier.

20. The composition of Claim 19, wherein the fumonisin, or an analog thereof, is present in an amount between 5 and 500 mg.

5 21. The composition of Claim 19, wherein the fumonisin, or an analog thereof, is present in an amount between 25 and 75 mg.

22. The composition of Claim 19, wherein the analog has a  
10 hydroxyl group at the first carbon.

23. The composition of Claim 19, wherein the analog has a 2-amino-3,5-diol head group.

15 24. The composition of Claim 19, wherein the fumonisin is Fumonisin B<sub>1</sub>.

25. The composition of Claim 19, wherein the fumonisin is Fumonisin B<sub>2</sub>.

20

26. The composition of Claim 19, wherein the fumonisin analog is AAL toxin.

27. A method of treating an abnormal condition in a  
25 subject associated with the ingestion of a fumonisin, or an analog thereof, which results in the depletion of a sphingolipid in the subject, comprising adding an amount of the sphingolipid to the subject sufficient to treat the condition.

30

28. The method of Claim 27, wherein the sphingolipid is sphingosine.

29. A method of treating an abnormal condition in a  
35 subject associated with the ingestion of a fumonisin, or an analog thereof, which results in the accumulation of a sphingolipid comprising adding an amount of an inhibitor

of the sphingolipid to the subject sufficient to treat the condition.

30. The method of Claim 29, wherein the sphingolipid is sphinganine.

5

31. A method of detecting the consumption of a fumonisin, or an analog thereof, in a subject comprising (1) detecting, in a sample from the subject, the state of the metabolic pathway of sphingolipids and (2) comparing the  
10 state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the consumption of a fumonisin or fumonisin analog.

15 32. The method of Claim 31, wherein the change in the metabolic pathway is an increase in sphinganine.

33. The method of Claim 31, wherein the change in the biosynthetic pathway is a decrease in ceramide.

20

34. A method of detecting the presence of a fumonisin, or an analog thereof, contamination in a sample from a food or feed comprising detecting a reaction of the metabolic pathway of sphingolipids, the presence of the reaction  
25 indicating the presence of a fumonisin or fumonisin analog contamination.


35. The method of Claim 34, wherein the reaction is the prevention of the conversion of sphinganine or an analog.  
30 thereof to dihydroceramide or an analog thereof by ceramide synthase.

36. The method of Claim 34, wherein the reaction is the conversion of sphingosine to ceramide or an analog thereof  
35 by sphingosine-N-acyltransferase.

37. A method of diagnosing an abnormal condition in a subject associated with an alteration in sphingolipid metabolism comprising detecting the state of the metabolic pathway of sphingolipids in a subject and comparing the state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the presence of an abnormal condition.

38. The method of Claim 37, wherein the state of the pathway is an increase in sphinganine and the abnormal condition is esophageal cancer.

39. A compound in the form of a racemic mixture or a single isomer having the formula:



wherein the Spacer Group is selected from the group consisting of alkyl (straight chain or branched,  $C_1 - C_{20}$ ), hydroxyalkyl (straight chain or branched,  $C_1 - C_{20}$ ) and dihydroxyalkyl (straight chain or branched,  $C_1 - C_{20}$ ); Z is selected from the group consisting of H, O, NH, NQ, NQC(O), NHC(O),  $\text{CO}_2$ ,  $\text{C(O)NH}$ , and  $\text{C(O)NQ}$ , wherein Q is an alkyl (straight chain or branched,  $C_1 - C_6$ ); W is selected from the group consisting of no substituent, H, alkyl (straight chain or branched,  $C_1 - C_6$ ), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched,  $C_1 - C_6$ ) or halo),  $\text{C(O)(CH}_2\text{)}_n\text{CO}_2\text{H}$  (where  $n = 1 - 6$ ),  $\text{C(O)(CH}_2\text{)}_n\text{CW}'_2\text{CO}_2\text{H}$ , where W' is selected independently from H, alkyl (straight chain or branched,  $C_1 - C_6$ ), aryl (phenyl, substituted phenyl such as substitution with alkyl (straight chain or branched,  $C_1 - C_6$ ) or halo), and  $(\text{CH}_2)_n\text{CO}_2\text{H}$ , wherein  $n = 1 - 6$ ; X is

5

- 10

15

20

25

30


ABSTRACT OF THE DISCLOSURE

This invention provides a method of altering the metabolism of sphingolipids in a cell comprising  
5 contacting the cell with a fumonisin, or an analog thereof. The invention also provides a method of detecting the consumption of a fumonisin or a fumonisin analog in a subject comprising (A) detecting, in a sample from the subject, the state of the metabolic pathway of  
10 sphingolipids and (B) comparing the state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the consumption of a fumonisin or a fumonisin analog. Also provided is a method of detecting the presence of a  
15 fumonisin or fumonisin analog contamination in a sample from a food or feed comprising detecting a reaction of the metabolic pathway of sphingolipids, the presence of the reaction indicating the presence of a fumonisin or fumonisin analog contamination. Furthermore, novel  
20 fumonisin analogs and compositions comprising fumonisins and fumonisin analogs are provided.


25

30 mmm/c:\wpf\patwork\apps.91\merrill.020


Figure 1




Sphingosine




Fumonisin B<sub>1</sub>




Fumonisin B<sub>2</sub>




Fumonisin B<sub>3</sub>



Fumonisin B<sub>4</sub>




Alternaria toxins  
(AAL toxins)  
 $R_1 = \text{H or R}$



Tricarballic acid



Fumonisin Analogs



## Figure 2

5

Figure 4





Figure 5






Figure 6




Figure 7




Figure 8





Figure 9




a.  $\text{CH}_2\text{N}_2$ ; b. DIBAL; c. LiCCR; d. Peracid; e.  $\text{NaBH}_3\text{CN}$ ; f.  $\text{H}^+$

R = alkyl (straight chain or branched,  $\text{C}_8 - \text{C}_{20}$ ), hydroxy alkyl, amino alkyl, alkylcarboxy (same definition of alkyl), aryl, esters of the hydroxyalkyl and alkylcarboxy groups, amides of the aminoalkyl and alkylcarboxy groups.

Figure 10

Figure 11



$R$  = alkyl (straight chain or branched,  $C_8$ - $C_{20}$ ), hydroxy alkyl, amino alkyl, alkylcarboxy (same definition of alkyl), aryl, esters of hydroxyalkyl and alkylcarboxy groups, amides of the aminoalkyl and alkyl carboxy groups

$R'$  = H,  $CH_3$ ,  $C_2H_5$ ,  $CH_2O$ -Protecting Group

(\*) Epoxide opening and removal of the BOC group may be more efficiently achieved using two discrete hydrolysis steps

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(X) Original                      ( ) Supplemental                      ( ) Substitute                      ( ) PCT

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "METHOD OF ALTERING SPHINGOLIPID METABOLISM AND DETECTING FUMONISIN ENGESTION AND CONTAMINATION", which is described and claimed in the specification

(check one) [ ] which is attached hereto, or  
[X] which was filed on August 5, 1991, as  
Application Serial No. 07/740,426 and with  
amendments through \_\_\_\_\_ (if applicable), or  
[ ] in International Application No. PCT/\_\_\_\_\_, filed  
\_\_\_\_\_, and as amended on \_\_\_\_\_  
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate relating to this subject matter having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
<u>N/A</u>				
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>                    </u>	<u>                    </u>	<u>                    </u>		
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>N/A</u>		
(Application Serial No.)	(Filing Date)	(Status-patented, pending, abandoned)
<u>                    </u>	<u>                    </u>	<u>                    </u>
(Application Serial No.)	(Filing Date)	(Status-patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

William H. Needle (Reg. No. 26,209); Sumner C. Rosenberg (Reg. No. 28,753); David G. Perryman (Reg. No. 33,438); Mary L. Severson (Reg. No. 34,927); and Donald E. Hayes, Jr. (Reg. No. 33,245).

Address all telephone calls to William H. Needle at telephone no. (404) 688-0770.  
Address all correspondence to:

William H. Needle  
NEEDLE & ROSENBERG, P.C.  
133 Carnegie Way, N.W.  
Suite 400  
Atlanta, Georgia 30303

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor: Alfred H. Merrill, Jr.

Inventor's signature Alfred H. Merrill Date 8/29/91  
Residence: 1021 Bramwell Lane Citizenship: U.S.A.  
Post Office Address: Stone Mountain, GA 30083  
SWORN TO AND SUBSCRIBED TO BEFORE ME THIS 29th DAY OF AUGUST, 1991. Jane S. Penrod  
My Commission Expires: Notary Public, DeKalb County, Georgia  
My Commission Expires Oct. 10, 1993 Notary Public

Full name of second joint inventor: Elaine W. Wang

Inventor's signature Elaine W. Wang Date 8/29/91  
Residence: 2879 Greenbrook Way, N.E. Citizenship: U.S.A.  
Post Office Address: Atlanta, Georgia 30345  
SWORN TO AND SUBSCRIBED TO BEFORE ME THIS 29th DAY OF AUGUST, 1991. Jane S. Penrod  
My Commission Expires: Notary Public, DeKalb County, Georgia  
My Commission Expires Oct. 10, 1993 Notary Public

Full name of third joint inventor: Dennis C. Liotta

Inventor's signature Dennis C. Liotta Date 8/29/91  
Residence: 793 Post Road Way Citizenship: U.S.A.  
Post Office Address: Stone Mountain, Georgia 30088  
My Commission Expires: Notary Public, DeKalb County, Georgia  
My Commission Expires Oct. 10, 1993

Notary Public, DeKalb County, Georgia  
My Commission Expires Feb. 7, 1991

Sara J. Shaffer

Full name of fourth joint inventor: Ronald T. Riley

Inventor's signature Ronald T. Riley Date 9/3/91

Residence: 4209 Old Lexington Road Citizenship: U.S.A.

Post Office Address: Athens, Georgia 30305

name: wp/patent/appa91/menil.doc

91018 DV2

Docket No.: EMU/125 Div. (18085/105133)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alfred H. Merrill, Jr., et al.

Serial No.: 08/627,499

Filed: April 4, 1996

Title: Method of Altering Sphingolipid Metabolism and Detecting Fumonism Ingestion and Contamination

Assistant Commissioner for Patents  
Washington, D.C. 20231

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST  
AND REVOCATION OF PRIOR POWERS**

Sir:

As owner of the entire interest of the above-identified patent application, all powers of attorney previously given are hereby revoked and the following attorney and agent are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Sherry M. Knowles

Registration No. 33,052

Jacqueline Haley

Registration No. P-41,457


Please send all correspondence relating to the above patent application to:

Sherry M. Knowles, Esq.  
King & Spalding  
191 Peachtree Street  
Atlanta, Georgia 30303-1763

Please direct all telephone calls to:

Sherry M. Knowles (404) 572-3541  
Jacqueline Haley (404) 572-3478

Emory University

By: 

Title: Director of Licensing and Patent Counsel

Date: October 9, 1997